Frida returns to research, on 80%
From November 1st, Frida will spend 80% of her time as a researcher in the Haug group. The researcher position is affiliated with the 180N Norwegian Nuclear Medicine Consortium funded through the Trond Mohn Foundation. Frida will be part of the Tracer Development Center within the consortium and will work on new methods for 18F radiolabeling of organosilanes and functionalization of bioactive compounds with chelator moieties for introduction of radiometals. The project will be carried out in collaboration with the LeRoux group and the PET centre at Haukeland University Hospital.
